JP5797837B2 - 組換えフューリン製剤 - Google Patents

組換えフューリン製剤 Download PDF

Info

Publication number
JP5797837B2
JP5797837B2 JP2014513796A JP2014513796A JP5797837B2 JP 5797837 B2 JP5797837 B2 JP 5797837B2 JP 2014513796 A JP2014513796 A JP 2014513796A JP 2014513796 A JP2014513796 A JP 2014513796A JP 5797837 B2 JP5797837 B2 JP 5797837B2
Authority
JP
Japan
Prior art keywords
furin
composition
ppm
sugar
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014513796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014519506A5 (enExample
JP2014519506A (ja
Inventor
マインハルト ハスラッハー
マインハルト ハスラッハー
アンジェイ シトコウィクズ
アンジェイ シトコウィクズ
キャサリーン ホワイト
キャサリーン ホワイト
ケン フランケ
ケン フランケ
Original Assignee
バクスター、インターナショナル、インコーポレイテッド
バクスター ヘルスケア エス．エー．
バクスター ヘルスケア エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクスター、インターナショナル、インコーポレイテッド, バクスター ヘルスケア エス．エー．, バクスター ヘルスケア エス．エー． filed Critical バクスター、インターナショナル、インコーポレイテッド
Publication of JP2014519506A publication Critical patent/JP2014519506A/ja
Publication of JP2014519506A5 publication Critical patent/JP2014519506A5/ja
Application granted granted Critical
Publication of JP5797837B2 publication Critical patent/JP5797837B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21075—Furin (3.4.21.75)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014513796A 2011-06-02 2012-06-04 組換えフューリン製剤 Expired - Fee Related JP5797837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492712P 2011-06-02 2011-06-02
US61/492,712 2011-06-02
PCT/US2012/040790 WO2012167271A1 (en) 2011-06-02 2012-06-04 Formulations of recombinant furin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015161719A Division JP6064007B2 (ja) 2011-06-02 2015-08-19 組換えフューリン製剤

Publications (3)

Publication Number Publication Date
JP2014519506A JP2014519506A (ja) 2014-08-14
JP2014519506A5 JP2014519506A5 (enExample) 2015-07-30
JP5797837B2 true JP5797837B2 (ja) 2015-10-21

Family

ID=46705014

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014513796A Expired - Fee Related JP5797837B2 (ja) 2011-06-02 2012-06-04 組換えフューリン製剤
JP2015161719A Expired - Fee Related JP6064007B2 (ja) 2011-06-02 2015-08-19 組換えフューリン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015161719A Expired - Fee Related JP6064007B2 (ja) 2011-06-02 2015-08-19 組換えフューリン製剤

Country Status (14)

Country Link
US (2) US8877473B2 (enExample)
EP (1) EP2714087B1 (enExample)
JP (2) JP5797837B2 (enExample)
KR (1) KR102050609B1 (enExample)
CN (1) CN103889454B (enExample)
AR (1) AR086672A1 (enExample)
AU (2) AU2012261813B2 (enExample)
BR (1) BR112013030880B1 (enExample)
CA (1) CA2837948C (enExample)
ES (1) ES2715289T3 (enExample)
RU (1) RU2610436C2 (enExample)
SG (2) SG195261A1 (enExample)
TW (1) TWI586802B (enExample)
WO (1) WO2012167271A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4443135A3 (en) * 2013-08-20 2024-12-18 Yokogawa Fluence Analytics, Inc. Characterization of polymer and colloid solutions
TWI743023B (zh) * 2014-05-21 2021-10-21 日商Ｋｍ生物醫藥股份有限公司 基質金屬蛋白酶 7(mmp-7)聚集體之單體化方法
TWI666319B (zh) 2014-08-12 2019-07-21 美商巴克斯歐塔公司 在分泌ｆｕｒｉｎ之哺乳動物表現系統中生產經完全加工且具功能性之因子Ｘ
CA3068121A1 (en) 2017-06-23 2018-12-27 Baxalta Incorporated Purification of factor viii subspecies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9000917A (nl) 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
US6596526B1 (en) 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
ATE507822T1 (de) * 2003-12-19 2011-05-15 Novo Nordisk Healthcare Ag Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
DE102006008613A1 (de) * 2006-02-24 2007-08-30 Dade Behring Marburg Gmbh Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
US8343748B2 (en) * 2007-05-22 2013-01-01 Baxter International Inc. Preparative purification process for human furin
SG10201805749QA (en) 2007-12-31 2018-08-30 Baxalta Inc Substantially animal protein-free recombinant furin and methods for producing same

Also Published As

Publication number Publication date
ES2715289T3 (es) 2019-06-03
BR112013030880A2 (pt) 2017-06-20
US20120329128A1 (en) 2012-12-27
AU2012261813B2 (en) 2017-04-20
RU2610436C2 (ru) 2017-02-10
TW201249989A (en) 2012-12-16
US8877473B2 (en) 2014-11-04
EP2714087B1 (en) 2018-10-31
JP2016006106A (ja) 2016-01-14
EP2714087A1 (en) 2014-04-09
AU2017202050A1 (en) 2017-04-20
US20150079068A1 (en) 2015-03-19
CA2837948C (en) 2018-08-21
US9662376B2 (en) 2017-05-30
AU2012261813A1 (en) 2013-12-19
SG10201604488TA (en) 2016-07-28
JP2014519506A (ja) 2014-08-14
JP6064007B2 (ja) 2017-01-18
RU2013157927A (ru) 2015-07-20
BR112013030880B1 (pt) 2022-04-12
CA2837948A1 (en) 2012-12-06
CN103889454B (zh) 2017-04-05
KR20140050625A (ko) 2014-04-29
SG195261A1 (en) 2013-12-30
AR086672A1 (es) 2014-01-15
CN103889454A (zh) 2014-06-25
KR102050609B1 (ko) 2019-11-29
TWI586802B (zh) 2017-06-11
WO2012167271A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
US20250121066A1 (en) Stabilized factor ix formulations containing trehalose
US10758599B2 (en) Stabilized liquid and lyophilized ADAMTS13 formulations
JP6064007B2 (ja) 組換えフューリン製剤
US12005144B2 (en) Lyophilized formulations for factor XA antidote
HK1196533A (en) Formulations of recombinant furin
HK1196533B (en) Formulations of recombinant furin
HK40001910B (en) Lyophilized formulations for factor xa antidote
HK1188936A (en) Stabilized factor ix formulations containing trehalose

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150609

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150609

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150819

R150 Certificate of patent or registration of utility model

Ref document number: 5797837

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees